摘要
目的探讨在开展精神分裂症治疗工作期间,观察阿立哌唑+利培酮药物联合施治后表现出的安全性以及获得的临床疗效。方法选择我院2015年4月—2017年1月收治的163例精神分裂症患者作为实验对象;通过数字奇偶法展开分组;对照组(82例):应用利培酮药物施治;观察组(81例):应用阿立哌唑+利培酮药物施治;对精神分裂症临床疗效以及安全性展开对比。结果与对照组精神分裂症患者临床疗效以及安全性比较,观察组精神分裂症患者改善程度显著,差异具有统计学意义(P<0.05)。结论充分应用阿立哌唑+利培酮药物对精神分裂症患者施治,对于精神分裂症疗效提高以及安全性的改善可以做出双重保证,从而优化精神分裂症患者的预后能力以及生活能力。
Objective Investigate the safety and clinical efficacy of aripiprazole ＋ risperidone in the treatment of schizophrenia. Methods 163 patients with schizophrenia who admitted to our hospital from April 2015 to January 2017 were selected as experimental subjects and grouping with digital parity method. Control group （82 cases） ： treated with risperidone; observation group （81 cases） ： treated with aripiprazole ＋ risperidone. Clinical efficacy and safety of schizophrenia were compared. Results Compared with the clinical efficacy and safety of patients with schizophrenia in the control group, the improvement degree of patients with schizophrenia in observation group was significant （P〈0.05）.Conclusion Full application of aripiprazole ＋ risperidone drugs in patients with schizophrenia, can make a double guarantee for the improvement of schizophrenia and safety, so as to optimize the prognosis of schizophrenic patients and living ability.
出处
《中国继续医学教育》
2017年第22期173-174,共2页
China Continuing Medical Education
